Optimizing Aetna Xtandi Prior Authorization Workflows

Streamlining Aetna Xtandi prior authorization is critical for timely patient access to this essential therapy. Klivira automates the submission and tracking process, reducing administrative burden.

Xtandi (enzalutamide) is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans due to its cost and clinical criteria. For revenue cycle directors and prior authorization coordinators, navigating Aetna's specific requirements for Xtandi can be complex. Understanding Aetna's submission channels, policy access, and electronic PA capabilities is key to accelerating approvals and minimizing denials.

Understanding Xtandi and Aetna's Benefit Structure

Xtandi (enzalutamide) is an androgen receptor inhibitor used in the treatment of prostate cancer. As a specialty medication, it typically falls under the pharmacy benefit, managed by CVS Caremark, Aetna's PBM. However, some specialty injectables and infused medications can be managed under the medical benefit, necessitating careful verification of the specific benefit assignment for oral specialty drugs like Xtandi.

Aetna's Prior Authorization Submission Channels for Specialty Drugs

Aetna, a CVS Health-owned national insurer, utilizes distinct channels for prior authorization submissions. For pharmacy-benefit medications like Xtandi, submissions route primarily through CoverMyMeds or Surescripts ePA for retail scenarios. Mail-order and case-managed scenarios may utilize CVS Caremark's direct provider portal. For medical-benefit prior authorizations, Aetna generally routes requests through the Availity provider portal, which serves as their primary multi-payer workspace, and also accepts X12 278 transactions via clearinghouses for applicable procedure categories.

Accessing Aetna's Medical Necessity Criteria for Xtandi

Aetna's medical-necessity criteria, including those for specialty medications, are published as Clinical Policy Bulletins (CPBs) in the public Aetna CPB library. Each CPB is versioned, dated, and structured by topic, with a canonical CPB number. Providers should reference the specific CPB number and review date when citing Aetna policy for Xtandi. These CPBs detail the clinical indications, step-therapy requirements, and other criteria necessary for approval.

Electronic Prior Authorization (ePA) and Da Vinci PAS Posture

Aetna supports electronic prior authorization for pharmacy benefits through established ePA partners such as CoverMyMeds and Surescripts. For medical-benefit ePA, the landscape is more fragmented, relying on channels like Availity and X12 278. While Aetna participates in HL7 connectathons, including those related to Da Vinci PAS IG, Klivira does not assert Aetna is live on Da Vinci PAS without a sourced disclosure. Klivira integrates with these diverse channels to standardize ePA submissions.

Aetna Prior Authorization Turnaround Times and Compliance

Prior authorization turnaround times for Aetna are governed by state insurance regulations for commercial plans, NCQA Utilization Management accreditation standards, and for Medicare Advantage and Medicaid managed-care (Aetna Better Health) lines, by CMS-0057-F. This CMS rule mandates 72-hour decisions for standard PA requests and 24-hour decisions for expedited requests for impacted lines, with phased compliance through 2027. Klivira's platform tracks submissions against these regulatory timeframes to ensure compliance and prompt follow-up.

Common Denial Reasons and Appeal Pathways for Xtandi with Aetna

Denial reasons for specialty drugs like Xtandi often include medical necessity/insufficient documentation, failure to meet step-therapy requirements, or off-label use without compendium support. Aetna returns denial reasons via X12 835/277 transactions or portal status updates, utilizing CARC and RARC vocabularies. The appeal pathway typically includes reconsideration, peer-to-peer review, and formal appeal, with expedited options for urgent care needs. Klivira helps identify common denial patterns and supports efficient appeal submission.

Frequently asked questions

How do I submit an Aetna Xtandi prior authorization request?

For pharmacy-benefit Xtandi, submissions are typically made through ePA partners like CoverMyMeds or Surescripts, or via the CVS Caremark provider portal for mail-order. For medical-benefit specialty drugs, the Availity portal or X12 278 transactions are common. Klivira integrates with these channels to streamline submission.

Where can I find Aetna's specific medical necessity criteria for Xtandi?

Aetna publishes its medical necessity criteria, including those for specialty medications, in Clinical Policy Bulletins (CPBs) available in their public CPB library. Always reference the specific CPB number and its most current review date for accurate requirements.

What are the typical turnaround times for Aetna prior authorizations?

Turnaround times vary by line of business and state. Commercial plans adhere to state regulations and NCQA standards, while Medicare Advantage and Medicaid managed-care plans are subject to CMS-0057-F, which mandates 72-hour standard and 24-hour expedited decisions.

What are common reasons for Aetna to deny Xtandi prior authorization requests?

Common denial reasons include insufficient documentation to support medical necessity, failure to meet required step-therapy protocols, or off-label use without appropriate compendium support. Klivira helps identify and address these issues proactively.

Does Aetna support electronic prior authorization (ePA) for Xtandi?

Yes, Aetna supports ePA for pharmacy-benefit medications like Xtandi through partners such as CoverMyMeds and Surescripts. Klivira's platform connects directly to these ePA vendors, automating the submission process.